BiotechTube

Kedrion IVIG 10%

Phase 3Recruiting
0 views this week 0 watching⚡ Active📊Featured in Mid-Cap Catalyst Watch
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Primary Immune Thrombocytopenia (ITP)

Conditions

Chronic Primary Immune Thrombocytopenia (ITP)

Trial Timeline

Aug 13, 2025 → Aug 1, 2026

NCT ID
NCT07059000

About Kedrion IVIG 10%

Kedrion IVIG 10% is a phase 3 stage product being developed by ICON plc. for Chronic Primary Immune Thrombocytopenia (ITP). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07059000. Target conditions include Chronic Primary Immune Thrombocytopenia (ITP).

What happened to similar drugs?

20 of 20 similar drugs in Chronic Primary Immune Thrombocytopenia (ITP) were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07059000Phase 3Recruiting

Competing Products

20 competing products in Chronic Primary Immune Thrombocytopenia (ITP)

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)Lyra TherapeuticsPhase 2
25
480 Mometasone Furoate Sinus Drug DepotLyra TherapeuticsPhase 1
19
LYR-210 + Sham procedure controlLyra TherapeuticsPhase 3
30